Enrollment jumps after lawmakers ease access to Georgia’s medical cannabis program

💊 Georgia’s recent expansion of medical cannabis access represents a policy shift that may increase patient inquiries in clinical practice, though the available summary offers limited detail about specific programmatic changes. Healthcare providers should anticipate that patients may present with cannabis as a treatment consideration for conditions like chronic pain, epilepsy, or chemotherapy-related nausea, necessitating updated knowledge about product variability, dosing, and drug interactions. A key caveat is that despite expanded access, high-quality clinical evidence supporting cannabis efficacy and safety remains limited for most indications, and patients may have unrealistic expectations shaped by policy changes rather than robust data. Providers should be prepared to conduct thorough risk-benefit discussions, document cannabis use in patient records, and recognize that regulatory expansion does not equate to clinical evidence advancement. The practical implication is to develop a structured approach to cannabis discussions in your practice: clarify whether patients are seeking medical guidance or have already obtained products through